Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by CommonCentsforDollarson Dec 03, 2020 1:40pm
187 Views
Post# 32029589

RE:3 Popular Robinhood Stocks Wall Street Loves

RE:3 Popular Robinhood Stocks Wall Street LovesNot even a mention of Sweetwater... 

Algo's playing jedi mind games as the tape gets painted.

Today printed a higher high and a higher low than yesterday.
Tomorrow will be interesting.
 

Ventura2020 wrote:

Aphria

Millennial investors also love investing in marijuana stocks. What you might find surprising is that there's a pot stock Wall Street likes, too: Aphria (NASDAQ: APHA. Of the 12 analysts covering Aphria's stock, 11 of them (92% currently rate it a buy.
Despite most Canadian pot stocks losing money hand over fist, Aphria has delivered a rare quarterly profit from time to time. It's been able to achieve intermittent profits thanks to its acquisition of drug distribution company CC Pharma. This business segment, which has nothing to do with cannabis, is relatively low margin, but generates predictable sales and cash flow.
Aphria has also delivered impressive net cannabis sales growth in recent quarters. With many of its peers struggling, Aphria more than doubled its net marijuana sales in the August-ended quarter. Given its broad international presence, the company is beginning to establish itself as a potential winner to our north. 
The one concern I have is that adult-use retail selling prices per gram are falling because recreational consumers favor value-based dried flower. Until we see a big uptick in high-margin derivative sales, the ongoing battle between legal and illicit channels could pressure Aphria's cannabis margins.

COULD pressure the margins. I think the legal market is pressuring the illicit market!



<< Previous
Bullboard Posts
Next >>